MannKind Corporation
NASDAQ:MNKD · NASDAQ Global Market
-$0.02 today
Vol 11.62M · Avg 5.73M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-11.5%
avg 21.1%
ROIC
5.8%
avg -6.8%
ROA
0.7%
avg -50.1%
Analysis
ROIC is currently the strongest return metric at 5.8% versus its period average of -6.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael E. Castagna | Chief Executive Officer & Director | $1.61M | — | 50 | $82,781.00 | 0.03% |
David Thomson | Executive Vice President, General Counsel & Secretary | $1.02M | — | 59 | $826,299.00 | 0.27% |
Stuart A. Tross | Chief People & Workplace Officer | $812,215.00 | — | 59 | $1.03M | 0.33% |
Christopher Prentiss | Chief Financial Officer | $753,319.00 | — | 51 | $338,924.00 | 0.11% |
Dominic Marasco | President of Endocrine Business Unit | $717,723.00 | — | 54 | $344,246.00 | 0.11% |
Sanjay Singh | Executive Vice President of Technical Operations | $364,529.00 | — | 60 | $221,000.00 | 0.07% |
Ajay Ahuja | Executive VP & Chief Medical Officer | — | — | 56 | $221,000.00 | 0.07% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$259,000.00
Sells
11
$2.98M
Net Sentiment
$2.72M
Net selling
Most Active
Castagna Michael
4 transactions
1–10 of 12
Analysis
Insiders reported 1 buys worth $259,000.00 and 11 sells worth $2.98M over the last 12 months. That adds up to net selling of $2.72M. Castagna Michael was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector

Vera Therapeutics, Inc.
NASDAQ:VERA
$2.49B

Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.19B

Aurinia Pharmaceuticals Inc.
NASDAQ:AUPH
$2.09B

Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
$1.92B

Nuvation Bio Inc.
NYSE:NUVB
$1.86B

Sionna Therapeutics, Inc.
NASDAQ:SION
$1.67B

AbCellera Biologics Inc.
NASDAQ:ABCL
$1.65B

Immunocore Holdings plc
NASDAQ:IMCR
$1.45B

Biohaven Ltd.
NYSE:BHVN
$1.41B

Janux Therapeutics, Inc.
NASDAQ:JANX
$842.20M
Who manages MNKD?
MannKind Corporation (MNKD) lists 7 active executives. The top listed executive is Stuart A. Tross, Chief People & Workplace Officer.
Are MNKD insiders buying or selling?
Recent insider activity shows net selling of $6.51M.
Explore More
Continue the stock analysis
Jump to another research area for this company.